An Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK-6482
Latest Information Update: 17 Jan 2024
Price :
$35 *
At a glance
- Drugs Belzutifan (Primary)
- Indications Biliary cancer; Colorectal cancer; Liver cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Von Hippel-Lindau disease
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 10 Jan 2024 Status changed from recruiting to completed.
- 12 Dec 2023 Planned End Date changed from 18 Dec 2023 to 29 Jan 2024.
- 07 Dec 2023 Planned primary completion date changed from 9 Dec 2023 to 20 Jan 2024.